Diabetes drug shows promise for kidney patients without diabetes
NCT ID NCT07344922
First seen Jan 19, 2026 · Last updated Jun 12, 2026 · Updated 18 times
Summary
This study tested whether dapagliflozin, a drug typically used for diabetes, can slow kidney decline, improve anemia, and protect the heart in 100 adults with chronic kidney disease who do not have diabetes. Participants took either the drug or a placebo daily for 12 months alongside their usual care. The goal is to find new ways to manage kidney disease and its complications without relying on diabetes treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Urology and Nephrology Center, Mansoura University
Al Mansurah, Dakahlia Governorate, 35511, Egypt
Conditions
Explore the condition pages connected to this study.